• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)

by MM360 Staff | Jun 17, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma

by MM360 Staff | Jun 17, 2025 | Myeloma News

Source: Pharmacy Times articles Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial. Read More

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

by MM360 Staff | Jun 10, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma

by MM360 Staff | Jun 9, 2025 | Myeloma News

Source: Pharmacy Times articles Cilta-cel shows promise as a CAR T-cell therapy, offering long-term remission for relapsed/refractory multiple myeloma patients without maintenance treatment. Read More

Sequencing Strategies and the Role of Combination Therapy

by MM360 Staff | Jun 6, 2025 | Myeloma News

Source: Pharmacy Times articles Panelists discuss how evolving treatment pathways at Emory Healthcare, including earlier use of emerging therapies and off-label combination treatments, are shaping the management of chronic graft-vs-host disease (cGVHD), with an...

ASCO 2025: Fixed-Duration Treatment Emerges as Future of Multiple Myeloma Management

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma. Read More
« Older Entries

Recent Content

  • A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
  • High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma
  • Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials
  • Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
  • You Are Not Alone While Building a Support Team During Cancer Care
  • Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma
  • When Treatment Ends, Support Shouldn’t Stop in Cancer Care
  • Sequencing Strategies and the Role of Combination Therapy
  • Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
  • Being in the Present Moment With Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT